Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seven Clinical Trial Read-Outs Due In Q4

Executive Summary

The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.


Related Content

Galectin Offers Subgroup Approach For Struggling NASH Candidate
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
Phase III Updates Bode Well For Filings Of Roche's Emicizumab In Hemophilia
Roche's Emicizumab Progresses Against Hemophilia's Next Big Challenge: Patients With Factor VIII Inhibitors
Patient Death Casts Cloud Over Roche Emicizumab Hemophilia Trial
Cytokinetics Seeks ALS Success By Focusing On Lung Function
Catalyst Collapses On FDA Firdapse Refusal
Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts